Literature DB >> 20064286

NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.

Peter L Greenberg, Cynthia K Rigsby, Richard M Stone, H Joachim Deeg, Steven D Gore, Michael M Millenson, Stephen D Nimer, Margaret R O'Donnell, Paul J Shami, Rashmi Kumar.   

Abstract

The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force to critically review the evidence for iron chelation and the rationale for treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS). The task force was charged with addressing issues related to tissue iron toxicity; the role of MRI in assessing iron overload; the rationale and role of treating transfusional iron overload in patients with MDS; and the impact of iron overload on bone marrow transplantation. This report summarizes the background data and ensuing discussion from the NCCN Task Force meeting on transfusional iron overload in MDS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20064286     DOI: 10.6004/jnccn.2009.0082

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  8 in total

Review 1.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

Review 2.  The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

Review 3.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2019-01-24       Impact factor: 10.047

4.  Looking to the future: incorporating genomic information into disparities research to reduce measurement error and selection bias.

Authors:  Alexandra E Shields; William H Crown
Journal:  Health Serv Res       Date:  2012-04-19       Impact factor: 3.402

Review 5.  Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-03       Impact factor: 10.047

Review 6.  Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes.

Authors:  Jayshree Shah; Phyllis McKiernan
Journal:  J Adv Pract Oncol       Date:  2016-11-01

Review 7.  Myelodysplastic syndromes: moving towards personalized management.

Authors:  Eva Hellström-Lindberg; Magnus Tobiasson; Peter Greenberg
Journal:  Haematologica       Date:  2020-05-21       Impact factor: 9.941

Review 8.  Quercetin attenuates neurotoxicity induced by iron oxide nanoparticles.

Authors:  Akram Bardestani; Shiva Ebrahimpour; Ali Esmaeili; Abolghasem Esmaeili
Journal:  J Nanobiotechnology       Date:  2021-10-18       Impact factor: 10.435

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.